Truist Financial Corp Decreases Position in Organon & Co. $OGN

Truist Financial Corp decreased its holdings in Organon & Co. (NYSE:OGN) by 16.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,451 shares of the company’s stock after selling 4,018 shares during the quarter. Truist Financial Corp’s holdings in Organon & Co. were worth $198,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of OGN. Hanson & Doremus Investment Management bought a new position in Organon & Co. in the 2nd quarter worth approximately $26,000. Ransom Advisory Ltd purchased a new stake in shares of Organon & Co. in the first quarter valued at $32,000. Brooklyn Investment Group raised its holdings in shares of Organon & Co. by 1,012.3% during the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock worth $46,000 after acquiring an additional 2,794 shares in the last quarter. Ridgewood Investments LLC purchased a new stake in shares of Organon & Co. during the second quarter worth $48,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Organon & Co. during the first quarter worth $51,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.1%

Shares of OGN opened at $9.28 on Friday. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of 3.45, a P/E/G ratio of 0.84 and a beta of 0.63. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05. The company has a 50-day moving average price of $9.93 and a two-hundred day moving average price of $10.02.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the company earned $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. Equities analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a $0.02 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.9%. Organon & Co.’s payout ratio is 2.97%.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.